ViewRay Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients
Study's primary objective of low grade 3+ toxicity was met; exploration of secondary outcomes underway to confirm local control rates and patient outcomes with MRIdian SMART
DENVER, Oct. 24, 2022 -- (Healthcare Sales & Marketing Network) -- ViewRay, In... Devices, Oncology ViewRay, MRIdian, MRI-guided radiation therapy, MRIdian A3i
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Marketing | Pancreas | Pancreatic Cancer | Pharmaceuticals | Radiation Therapy | Study | Toxicology